Publications

5808 Results

Disease and outcome disparities in multiple myeloma (MM): exploring the role of race/ethnicity and obesity in Cooperative Group Clinical Trials

Authors
S Ailawadhi;S Jacobus;R Sexton;AK Stewart;A Dispenzieri;MA Hussein;J Zonder;J Crowley;A Hoering;B Barlogie;R Orlowski;SV Rajkumar
Journal / Conference
Blood 128:1192; American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), oral
Year
2016
Research Committee(s)
Cancer Survivorship and Myeloma
Study Number(s)
S0204, S0232, SWOG-9321

Phase III randomized study of R-CHOP versus DA-EPOCH-R and molecular analysis of untreated diffuse large b-cell lymphoma: (Alliance) CALGB 50303

Authors
WH Wilson;S-H Jung;B Pitcher;E Hsi;RI Fisher;B Cheson;N Bartlett;S Smith;NW Johnston;B Kahl;L Staudt;K Blum;J Abramson;O Press;JW Friedberg;A Zelenetz;JP Leonard
Journal / Conference
Blood 128:469; American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), oral
Year
2016
Research Committee(s)
Lymphoma

Serum biomarkers predict outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial

Authors
JA Kanakry;F Hong;O Martinez-Maza;SJ Horning;LI Gordon;RD Gascoyne;LL Gellert;M Lemas;B Cheson;R Advani;B Pohlman;L Teston;VP Kenkre;JN Winter;P Stiff;J Tuscano;JW Friedberg;J Polikoff;LM Dreosti;JP Kuebler;S Robinson;DS Morgan;RI Fisher;N Bartlett;P Laneuville;B Kahl;RF Ambinder
Journal / Conference
Blood 128:2992; American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), poster
Year
2016
Research Committee(s)
Lymphoma
Study Number(s)
E2496

A Phase 1/2 Study of G-CSF, cladribine, cytarabine, and dose-escalated mitoxantrone (G-CLAM) in adults with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS): final results from a phase 1/2 study

Authors
A Halpern;E Estey;EM Huebner;M Othus;KF Orlowski;BL Scott;HA Smith;PS Becker;M-B M Percival;PC Hendrie;AM Perdue;T Chen;S Buckley;H Erba;R Walter
Journal / Conference
Blood 128:1068; American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), oral
Year
2016
Research Committee(s)
Leukemia
Study Number(s)
S0106

SWOG S1203: A randomized phase III study of standard cytarabine plus daunorubicin (7+3) therapy versus idarubicin with high dose cytarabine (IA) with or without vorinostat (IA+V) in younger patients with previously untreated acute myeloid leukemia (AML)

Authors
G Garcia-Manero;M Othus;J Pagel;J Radich;M Fang;DA Rizzieri;G Marcucci;S Strickland;MR Litzow;ML Savoie;B Medeiros;M Sekeres;T Lin;G Uy;BL Powell;J Kolitz;R Larson;RM Stone;D Claxton;J Essell;S Luger;S Mohan;A Moseley;FR Appelbaum;H Erba
Journal / Conference
Blood 128:901; American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), oral
Year
2016
Research Committee(s)
Leukemia
Study Number(s)
S1203

Feasibility of allogeneic hematopoietic cell transplantation among high-risk AML patients in first complete remission: results of the transplant objective from the SWOG (S1203) randomized phase III study of induction therapy using standard 7+3 therapy or idarubicin with high-dose cytarabine (IA) versus IA plus vorinostat

Authors
J Pagel;G Garcia-Manero;M Fang;J Radich;DA Rizzieri;G Marcucci;S Strickland;MR Litzow;ML Savoie;S Spellman;D Confer;J Chell;M Brown;B Medeiros;M Sekeres;TL Lin;G Uy;BL Powell;J Kolitz;RA Larson;RM Stone;D Claxton;J Essell;S Luger;S Mohan;A Moseley;H Erba;F Appelbaum
Journal / Conference
Blood 128:1166; American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), oral
Year
2016
Research Committee(s)
Leukemia
Study Number(s)
S1203

A Phase 1 trial of inotuzumab in combination with CVP (cyclophosphamide, vincristine, prednisone) for relapsed/ refractory CD22+ acute leukemia (SWOG 1312) [ http://www.bloodjournal.org/content/128/22/1634]

Authors
A Advani;A Moseley;M Liedtke;M O'Donnell;M Othus;M Mims;K O'Dwyer;H Erba
Journal / Conference
Blood 128:1634; American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), poster
Year
2016
Research Committee(s)
Leukemia
Study Number(s)
S1312

Improved prognostic significance genomic and transcriptional prognostic biomarkers by examining enriched populations of AML blasts: a SWOG report

Authors
EL Pogosova-Agadjanyan;A Moseley;BL Wood;F Appelbaum;TR Chauncey;H Erba;J Godwin;M Fang;Kopecky;AF List;M Othus;J Radich;I-M Chen;CL Willman;S Meshinchi;D Stirewalt
Journal / Conference
Blood 128:2890; American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), poster
Year
2016
Research Committee(s)
Leukemia
Study Number(s)
S0106, S0112, SWOG-9031, SWOG-9333

Complete remissions (CRs) with azacitidine regimens compared to CRs with 7+3 induction chemotherapy and the effect on overall survival

Authors
M Othus;M Sekeres;S Nand;G Garcia-Manero;F Appelbaum;H Erba;E Estey
Journal / Conference
Blood 128:1613; American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), poster
Year
2016
Research Committee(s)
Leukemia
Study Number(s)
S0106, S0703, S1117, S1203

Comparable outcomes of patients eligible versus ineligible for SWOG leukemia studies

Authors
A Statler;M Othus;H Erba;T Chauncey;J Radich;S Coutre;A Advani;S Nand;F Ravandi;S Mukherjee;M Sekeres
Journal / Conference
Blood 128:4002; American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), poster
Year
2016
Research Committee(s)
Leukemia
Study Number(s)
S0106, S0301, S0325, S0333, S0432, S0521, S0530, S0605, S0703, S0805, S0910, S0919, S1117